Corbus Pharmaceuticals Holdings, Inc. filings document a clinical-stage biotechnology issuer focused on oncology and obesity. The record includes Form 8-K material-event reports for clinical and regulatory disclosures involving CRB-701 and CRB-913, Regulation FD corporate presentations and risk language tied to product development, trial timelines and business strategy.
Proxy and governance filings cover board matters, executive compensation, equity awards, employment agreements and officer or director changes. The filings also provide formal disclosure categories for operating and financial results and the governance framework supporting the company’s drug-development pipeline.
A shareholder of CRBP has notified an intention to sell 17,000 shares of common stock through Stifel Nicolaus & Company Inc. The proposed sale has an indicated value of $171,396.00 and is listed for trading on Nasdaq with a proposed sale date of 08/07/2026.
The planned sale is supported by equity awards consisting of restricted stock units granted as equity compensation, including 9,210 units dated 02/12/2025 and 7,790 units dated 01/31/2026.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company developing therapies in oncology and obesity, led by CRB-701, a Nectin-4–targeting antibody drug conjugate, and CRB-913, a peripherally restricted CB1 inverse agonist for obesity. For the six months ended June 30, 2026, it reported a net loss of approximately $58.0 million, compared with $34.6 million a year earlier, as research and development expenses rose to $51.0 million, driven by a $10.0 million CRB-701 development milestone to CSPC and higher clinical spending on both CRB-701 and CRB-913.
Cash, cash equivalents and investments totaled approximately $117.9 million at June 30, 2026, and management expects this to fund operations for at least twelve months from the report issuance. The company raised about $9.1 million in Q2 2026 through at-the-market stock sales, with an additional $6.7 million raised after quarter-end. CRB-913 showed a mean 2.9% placebo-adjusted weight loss by Day 14 in an obese Phase 1a cohort, and a 240-patient Phase 1b study completed last visits in August 2026, with data expected in September 2026. CRB-701 has fast track designations in cervical cancer and HNSCC, with a registrational 2L OPSCC study (TEMPO-1) expected to begin enrollment in September 2026; the CRB-601 program has been deprioritized.
Corbus Pharmaceuticals Holdings reported second-quarter 2026 results and corporate updates, highlighting progress in its oncology and obesity pipeline. The company obtained FDA clearance to proceed with TEMPO-1, a registrational Phase 3 study of CRB-701 in second-line oropharyngeal cancer, and plans to begin enrollment in September 2026. It also completed last patient last visit in the 240-patient CANYON-1 Phase 1b trial of CRB-913 in obesity, with topline data expected in September 2026, and strengthened leadership with a new Chief Medical Officer, Chief Business Officer and Board member.
For the quarter ended June 30, 2026, Corbus recorded a net loss of approximately $35.0 million, or $1.81 per basic and diluted share, compared with a net loss of approximately $17.7 million, or $1.44 per share, a year earlier. Operating expenses rose to approximately $36.2 million from $19.2 million, driven largely by increased clinical development spending, including a $10.0 million milestone payment under the CRB-701 license. Cash, cash equivalents and investments totaled $117.9 million as of June 30, 2026, which Corbus expects will fund operations into 2028 based on current plans.
Corbus Pharmaceuticals Holdings, Inc. filed an insider ownership report on Form 3 for Nicacio Leonardo Viana, who serves as Chief Medical Officer. The filing identifies him as a company officer but reports no stock transactions or derivative positions and includes no holdings entries for him.
BlackRock, Inc. reports beneficial ownership of common stock of Corbus Pharmaceuticals Holdings Inc. BlackRock and certain of its business units collectively beneficially own 1,093,434 shares of Corbus common stock, representing 5.9% of the outstanding class as of the reported date.
BlackRock has sole voting power over 1,081,182 shares and sole dispositive power over 1,093,434 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds from these shares, but no single client holds more than five percent of Corbus’s outstanding common stock.
The issuer with ticker CRBP filed a notice that affiliate Dominic Smethurst may sell 23,025 shares of common stock through broker Stifel Nicolaus & Company Inc. on or about July 27, 2026 on the Nasdaq market.
The filing references common stock underlying restricted stock units granted on four dates in 2025–2026 and notes that Smethurst previously sold 3,334 shares of common stock for 31,001.00 on July 2, 2026.
Corbus Pharmaceuticals appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer under a two-year employment agreement effective August 3, 2026. His package includes a $545,000 annual base salary, a target bonus of up to 40% of base pay, and equity awards with an aggregate grant date fair value of $2.1 million, split roughly 75% stock options and 25% restricted stock units with multi‑year vesting.
The agreement provides severance of up to 18 months of base salary, COBRA reimbursement and accelerated equity vesting if he is terminated without cause or resigns for good reason during a defined change in control period, subject to a release and non‑compete. Corbus also highlighted upcoming milestones: initiation of the TEMPO‑1 registrational trial of CRB‑701 in second‑line oropharyngeal squamous cell carcinoma in summer 2026, a 250‑patient randomized study targeting overall response rate for potential accelerated approval, a planned similar trial in second‑line cervical cancer, and topline data from the CANYON‑1 Phase 1b obesity study of CRB‑913 in 240 patients expected in late summer 2026, with additional CRB‑701 data in first‑line OPSCC anticipated in early 2027.
Corbus Pharmaceuticals director Winston Kung sold 2,026 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $7.9137 per share, with individual sale prices ranging from $7.71 to $7.97.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026. After this transaction, Kung holds 12,140 shares directly, which includes 3,800 unvested restricted stock units subject to the grant’s vesting schedule.
Corbus Pharmaceuticals Holdings director Anne Altmeyer sold 2,412 shares of common stock in an open-market transaction at a weighted average price of $7.9137 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026.
These shares were sold in multiple trades at prices ranging from $7.71 to $7.97. After the sale, Altmeyer directly holds 7,579 shares of common stock, which includes 3,800 unvested restricted stock units that remain subject to the grant’s vesting schedule.
Corbus Pharmaceuticals Holdings, Inc. director John Kenneth Jenkins reported an open-market sale of 4,800 shares of common stock on June 10, 2026 at a weighted average price of $7.9137 per share, executed under a Rule 10b5-1 trading plan. Following this sale, he directly holds 3,833 shares of common stock and 3,800 unvested RSUs subject to the grant’s vesting schedule.